explore -WSS

explore

author：hotspot 2025-09-28 02:28:58 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

WSS

Vertex non

Novo Nordisk to expand supply of Wegovy for U.S. patients

What we need to know about Arena Bioworks

Complete sequence of Y chromosome published for first time

ARCH Venture Partners is raising $3 billion for a life sciences fund

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

knowledge

explore

Bluebird and the case for gene therapy profits

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Biden administration opens offers in Medicare drug price negotiations

Medicare proposal to cover medical devices draws a mixed reaction

FDA drug safety: Singulair case shows systemic surveillance flaws

23andMe had bad news about my health. I wish a person had delivered it

Novo Nordisk to expand supply of Wegovy for U.S. patients

Heart attack and stroke risk calculators need revising

Vertigo drug brings hope for rare neuron disorder, Niemann

What does generative AI mean for health care? We asked experts

Appeals court upholds limits to abortion pill

hotspot

FDA panel gives mixed vote on blood pressure devices

Australia’s approach to dialysis celebrates life

What AAP's gender

FDA panel gives mixed vote on blood pressure devices

Juul spent big to court Black leaders to promote its e

Neuroscience startup Neumora files for IPO

leisure time

hotspot

hotspot

leisure time